FDA says RRR Trading's EDP 7OH kratom extract shot is an adulterated supplement; its 7-OH ingredient lacks safety evidence.
What happened
FDA based this letter on a review of the company's product labeling for the EDP 7OH Mitragyna Speciosa Extract 50 mg shot, not on an inspection. The label declares 7-hydroxymitragynine (7-OH) as a dietary ingredient, and FDA says there is no information showing 7-OH was marketed as a dietary ingredient in the United States before October 15, 1994, and not enough safety information to give reasonable assurance it does not present a significant or unreasonable risk of illness or injury. FDA also cited adverse event reports linked to 7-OH products and reports that 7-OH has opioid-like effects.
What FDA found
The label lists 7-OH as a dietary ingredient, which puts it under the dietary supplement rules for ingredients.
Section 201(ff)(1)(F) of the Act (21 U.S.C. 321(ff)(1)(F))7-OH is a new dietary ingredient because FDA has no information that it was sold as a dietary ingredient in the U.S. before October 15, 1994.
Section 413(d) of the Act (21 U.S.C. 350b(d))The supplement is adulterated because there is not enough information to give reasonable assurance that 7-OH does not present a significant or unreasonable risk of illness or injury.
Section 402(f)(1)(B) of the Act (21 U.S.C. 342(f)(1)(B))Shipping the adulterated supplement across state lines is prohibited.
Section 301(a) of the Act
What FDA wants
FDA asks the company to reply in writing within 15 working days with the specific steps taken to correct the violations and prevent recurrence, plus related documents. If corrective actions cannot be finished in that time, the company must say why and when it will finish; if it believes the product is not in violation, it must give its reasoning and supporting information.
Who should pay attention
- kratom and botanical extract brands selling 7-OH products
- retailers and online sellers that stock kratom shots
- supplement firms that rely on an ingredient's past-market status
This is a summary. Read the original letter on fda.gov.